SAN MATEO, Calif., May 3, 2012 (GLOBE NEWSWIRE) -- NeurogesX, Inc. (Nasdaq:NGSX), a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, pain management therapies, today reported results for its first quarter ended March 31, 2012, and provided an update on recent developments.
